Litteratur:
l . BrownMS, Goldstein JL. Lipoprotein receptors in the
liver: control signals for plasma cholesterol traffic. J.
Clin. Invest. 1983; 72:743-7.
2. Mahley RW, Rall SCJr. Type
m
hyper-lipoproteinernia
(dysbetalipoproteinernia): The role of apalipoprotein E
in normal and abnormallipoproteinmetabolism. I: Seriver
CR, Beaudet AL, Sly WS, Valle D, red. The metabolic
basis of inherrited disease. 6 ed. New York: Mc Graw
Hilll989, 1195-1213.
3. Zannis VI, Breslow JL. Human very low density
apalipoprotein E isoprotein polymorphism is explained
by genetic variation and post-translational modification.
Biochernistry 1981; 20: 1033-41.
4. Mahley RW,Innerarity TL. Lipoprotein receptors and
cholesterol homeostasis. Biochem. Biophys. Acta 1983;
737: 197-222.
5. Mahley RW, Innerarity TL Weisgraber, Rall SC Jr,
Weisgraber KH, Taylor JM. Apolipoprotein E: genetic
variants provide insights into its structure and function.
Curr. Opin. LipidoL 1990:; 1: 87-95.
6. Davignon J, Gregg RE, Sing CF. Apolipoprotein E
polymorphism and atherosclerosis 1988: 8 1-21.
7. Hallman DM, Boerwinkle E, Saha N, Sandholzer C,
Menzel HJ, Csåzar A, Utermann G. The apalipoprotein
E polymorphism: Acomparison of allele frequencies and
effects in nine populations.
Am.
J. Hum.Genet. 1991; 49:
338-49.
8.Utermann G, Hess M, Steinmetz A. Polymorphism of
apalipoprotein E and occurrence of dyslipo-proteinernia
in man. Nature (London) 1977; 269: 604-7.
9.Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber
KH.Plasma lipoproteins: Apolipo-protein structure and
function. J. Lipid Res. 1984; 25:1277-94.
10. EhnholmC,LukkaM, Kuusi T, NikkiläEA,Utermann
G. Apalipoprotein E polymorphism in the Finnish popu–
lation: gene frequencies and relation to lipoprotein con-
30
centrations. J. Lipid Res. 1986; 27: 227-35.
11. Eggertsen G, Tegelman R, Ericsson S, Angelin B,
Berglund L. Apalipoprotein E polymorphism in a healty
Swedish population: Variation of allele frequency with
age and relation to serum lipid levels. Clin. Chem. 1993;
in press.
12. Berglund L, Wiklund O, Eggertsen G, Olofsson SO,
Eriksson M, Linden T, Bondjers G, Angelin B.
Apalipoprotein E phenotypes in familial hyper–
cholesterolaemia: importance for expression of disease
and response to therapy.
J.
Intern. Med. 1993; 233: 173-
8.
13. Hagve TA, Furuset T, Christophersen B, Ose L.
Apolipoprotein E-phenotyping- nyttig ved utredning av
hyperlipoproteinemi type III. Tidsskr. Nor. Lregeforen.
1993; 113: 853-6.
14. Davignon J, Bouthillier D, Nestruck AC, Sing CF.
Apolipoprotein E polymorphism and atherosclerosis:
lnsight from a study in octogenarians. Trans.
Am.
Clin.
Climatol. Ass. 1987; 99: 100-10.
15. van Bockxmeer FM, Mamotte DCS. Apolipoprotein
epsilon 4 homozygosity in young men with coronary
heart disease. Lancet 1992; 340: 879-80.
16.Mahley RW. Apalipoprotein E: cholesterol transport
protein with expanding role in cell biology. Science
1988; 240: 622-30.
17. StrittmatterWJ, Saunders AM, Schmechel D, Pericak–
Vance M, Enghild J, Salvesen GS, Roses AD.
Apolipoprotein E: High-avidity binding to B-amyloid
and increased frequency of type 4 allele in l te-onset
familial Alzheimer disease. Proc. Nat!. Acad. Sci. USA
1993; 90: 1977-81.
18. Hixson JE, Vernier DT. Restfiction isotyping of
human apolipoprotein E by amplification and cleavage
with Hha I,J, Lipid Res. 1990; 31: 545-8.
Klinisk kemi
i
Norden 3, 1993
